Fosamprenavir: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='340' side='right' caption='Fosamprenavir, better known as Lexiva, ([[3nu4]])' scene='Fosamprenavir/Fosamprenavir/2'> | ||
===Better Known as: Lexiva or Telzir=== | ===Better Known as: Lexiva or Telzir=== | ||
* Marketed By: Viiv Healthcare (Joint venture of Pfizer & GlaxoSmithKline)<br /> | * Marketed By: Viiv Healthcare (Joint venture of Pfizer & GlaxoSmithKline)<br /> | ||
| Line 14: | Line 14: | ||
===Drug Resistance=== | ===Drug Resistance=== | ||
The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]] | The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]] | ||
</StructureSection> | |||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | ||
